Table 2 Clinicopathological variables of patients according to the cutoff value of CRP/Alb ratio

Age (years)

48.71 ± 12.98

55.25 ± 13.92

<0.001^a

BMI

23.65 ± 3.37

23.41 ± 4.02

0.290^a

Gender

0.219^b

 Male

257 (65.40%)

125 (70.60%)

 Female

136 (34.60%)

52 (29.40%)

Pathological types

0.315^b

 Clear cell carcinoma

308 (81.20%)

43 (80.80%)

 Papillary carcinoma

26 (3.80%)

15 (8.50%)

 Others

59 (15.00%)

19 (10.70%)

Fuhrman-grade

<0.001^b

 I

92 (23.40%)

27(15.30%)

 II

178(45.30%)

71(40.10%)

 III

31(7.90%)

29(16.40%)

 IV

2(0.50%)

5(2.80%)

 Unknown

90(22.90%)

45(25.40%)

pTNM stage

<0.001^b

 I

313(79.60%)

84(47.50%)

 II

53(13.50%)

32(18.10%)

 III

22(5.60%)

37(20.90%)

 IV

5 (1.30%)

24(13.60%)

pT status

<0.001^b

 T1

318 (80.90%)

89 (50.30%)

 T2

54 (13.70%)

40 (22.60%)

 T3+ T4

21 (5.30%)

48 (27.10%)

pN status

<0.001^b

 N0

382 (97.20%)

153 (86.40%)

 N1

11 (2.80%)

24 (13.60%)

pM status

<0.001^b

 M0

390 (99.20%)

160 (90.40%)

 M1

3 (0.80%)

17 (9.60%)

Urine protein

0.188^b

 No

319 (81.20%)

141 (79.7%)

 Yes

15 (3.80%)

13 (7.3%)

 Unknown

59 (15.00%)

23 (13.00%)

ALP

0.018^b

 Normal

369 (93.90%)

156 (88.10%)

 Elevated

24 (6.10%)

21 (11.90%)

LDH

0.004^b

 Normal

335 (85.20%)

133 (75.10%)

 Elevated

58 (14.80%)

44 (24.90%)

CRE

0.001^b

 Normal

384 (97.70%)

162 (91.50%)

 Elevated

9 (2.30%)

15 (8.50%)

UA

0.468^b

 Normal

321 (81.70%)

140 (79.10%)

 Elevated

72 (18.30%)

37 (20.90%)

Total protein

0.144^b

 Normal

352 (89.60%)

151 (85.30%)

 Elevated

41 (10.40%)

26 (14.70%)

Serum globulin

 Normal

273 (69.50%)

87 (49.20%)

<0.001^b

 Elevated

120 (30.50%)

90 (50.80%)

NLR

<0.001^b

 < 1.85

205 (52.20%)

37 (20.90%)

  ≥ 1.85

188 (47.80%)

140 (79.10%)

PLR

<0.001^b

 < 153

324 (82.40%)

94 (53.10%)

  ≥ 153

69 (17.60%)

83 (46.90%)